Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio of T cell receptor (TCRs) targeting KRAS and TP53 mutations for the treatment of patients suffering with cancer.
12 Jan 2022
15 Dec 2021
A clinical-stage global biopharmaceutical group company AnHeart Therapeutics has completed a $61m Series B financing round that was led by new investor Octagon Capital.
08 Dec 2021
Recursion, a clinical-stage biotechnology company, has announced a collaboration with Roche and Genentech, a member of the Roche Group.
01 Dec 2021
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) to treat BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer patients.
04 Nov 2021
Stingthera has signed a clinical trial collaboration agreement with Merck to analyse the combination of investigational SNX281 and Keytruda (pembrolizumab) in some patients with advanced solid tumours and lymphoma.
25 Jun 2021
AbbVie is set to acquire Teneobio affiliate TeneoOne and its lead drug candidate TNB-383B, which is being developed to treat relapsed or refractory multiple myeloma (R/R MM).
15 Jun 2021
GlaxoSmithKline (GSK) and iTeos Therapeutics have signed an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody presently under phase I development as a potential treatment for cancer patients.
19 May 2021
Bristol-Myers Squibb (BMS) has agreed to obtain a worldwide exclusive licence to a cancer antibody programme, AGEN1777, and a second undisclosed target developed by immuno-oncology firm Agenus.
14 May 2021
Dr. Reddy's Laboratories has signed an agreement with Shenzhen Pregene Biopharma to acquire an exclusive license in India for PRG1801, Pregene's single domain antibody-based anti-BCMA chimeric antigen receptor T (CAR-T) cell therapy injection.
20 Apr 2021
The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC).